Navigation Links
Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
Date:7/1/2008

Submission of Five-Day Dosing Regimen sNDA Targeted for Fiscal Year-end

2008

WOODCLIFF LAKE, N.J., July 1, 2008 /PRNewswire/ -- Eisai Corporation of North America today announced the preliminary efficacy data from a trial initiated in 2002 comparing Dacogen(R) (decitabine) to Best Supportive Care (BSC) in elderly patients with myelodysplastic syndromes (MDS). The data did not demonstrate a statistically significant advantage of Dacogen treatment on median overall survival. However, response rates were similar to those observed in other clinical trials of Dacogen in patients with MDS. In the trial, conducted by the European Organisation for the Research and Treatment of Cancer (EORTC), Dacogen was administered on a three-day dosing schedule. In this study, the number of treatment cycles was limited. MDS is a potentially life-threatening group of bone marrow diseases that limit the production of functional blood cells.

Subsequent to database lock and the completion of data analysis, comprehensive results of the study, including secondary efficacy endpoints and safety data, will be presented by EORTC at an upcoming scientific forum.

Current Development

Eisai plans to submit a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration by the end of the fiscal year for a five-day regimen for Dacogen. The sNDA will be based on a North American, multi-center, open-label, single arm Phase II trial (DACO-020) in which patients received Dacogen every day for five days. The regimen was repeated every four weeks with no limit on the number of treatment cycles that patients could receive as long as they received clinical benefit or until their disease progressed. Median survival at the time of data analysis was 19.4 months and the one-year survival rate for patients treated with Dacogen was 66 percent. An overall complete response rate of 32 percent (International Working Group 2006 C
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
2. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
3. New Data Demonstrates 5-FU Personalized Chemotherapy Management (PCM(R)) Assay Provides Similar Performance to More Complicated Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
4. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
5. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
6. Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements
7. CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting
8. Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohns Disease
9. Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
10. Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
11. New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... SOUTH PLAINFIELD, N.J., July 30, 2015 PTC ... corporate update and reported financial results for the second ... is progressing on many fronts across the organization.  We ... largest Duchenne muscular dystrophy clinical trial ever conducted with ... W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. ...
(Date:7/30/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ) ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... notice it received on May 21, 2015 from the ... was below certain of the Exchange,s continued listing standards, ... the NYSE MKT Company Guide, due to the delay ...
(Date:7/30/2015)... LAKE, N.J. , July 30, 2015 ... simultaneously in the United States , ... the FDA, EMA and MHLW, respectively) for eribulin, for ... (STS) who have received prior chemotherapy for advanced or ... based on data from a pivotal global Phase 3 ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... 24 BioTrends Research Group, Inc. recently published its ... report is based on online ... interventional radiologists and interventional nephrologists). It provides an in-depth ... practice patterns related to both vascular access placement and ...
... Mass., Aug. 24 Echo Therapeutics, Inc. (OTC Bulletin ... needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal ... for transdermal drug delivery, today announced the completion of ... designed to evaluate the ability of Prelude to ablate ...
Cached Medicine Technology:Latest BioTrends Report Provides Comprehensive Market Landscape of the Dialysis Vascular Access Market 2Echo Therapeutics Announces Successful Completion of Clinical Trial for Prelude™ SkinPrep System and 4% Lidocaine Cream 2Echo Therapeutics Announces Successful Completion of Clinical Trial for Prelude™ SkinPrep System and 4% Lidocaine Cream 3
(Date:8/1/2015)... ... August 02, 2015 , ... AlignLife Office Coordinator Heather Pugh earned ... care for patients at this natural health care center in Winamac. , "Oftentimes patients ... said. "Heather's role is vital to our approach because we want to focus on ...
(Date:8/1/2015)... ... August 01, 2015 , ... ... in “a trending profession” that comprises a growing percentage of U.S. physicians, and ... , That was one part of the message delivered by John W. Becher, ...
(Date:8/1/2015)... Humble, TX (PRWEB) , ... August 01, 2015 , ... ... common concern among both men and women often causing pain and discomfort. Those who ... to this circulatory problem, and Northeast Houston Vein Center is doing what it can ...
(Date:8/1/2015)... ME (PRWEB) , ... August 01, 2015 , ... Tina ... Retail Champions.” , Wilcoxson was given that honor by the National Retail Federation, the ... retail industry. Wilcoxson was one of three Maine business owners to be named as ...
(Date:8/1/2015)... and Greenwich, CT (PRWEB) , ... August 01, ... ... a Great Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical ... — incorporating it into its portfolio of state-of-the-art clinics. , “Our acquisition of ...
Breaking Medicine News(10 mins):Health News:New Patient Advocate Enhances Natural Health Care 2Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Local Retail Advocate Wins National Recognition 2Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2
... 12, 2008) - Beta-blocker drugs may help prevent heart ... of death and major stroke, says a major study ... journal, The Lancet. , POISE is the worlds largest ... the effects of a beta-blocker versus placebo given to ...
... A.,Sandler, MD, a West Bloomfield diagnostic radiologist, was installed ... (MSMS) during,the 143rd annual meeting of the MSMS House ... of the Wayne State University School of Medicine, Doctor,Sandler ... at Henry,Ford Hospital and currently serves on the Michigan ...
... HARBIN, China, May 12 /Xinhua-PRNewswire-FirstCall/ -- China ... Yingxia" or "the,Company"), a leading provider in ... and distribution of organic nutritional food,products, supplements, ... Republic,of China ("PRC"), announced today it will ...
... hosts nine physicians from Chongqing Bureau of ... HealthPartners,Institute for Medical Education is hosting the ... to visit Minnesota. During their,three-month stay, the ... learn about health plan and hospital administration ...
... 12 Fairbank Farms, a national,ground beef producer, is ... at its Ashville, N.Y., facility and sold through Price,Chopper, ... Wholesale,distributor., The affected product may contain small pieces ... date of 05/13/08, 05/15/08, or a,"Julian date 124" on ...
... 12 PAREXEL International,Corporation (Nasdaq: PRXL ) announced ... 2008 Growth Stock Conference in Chicago, Illinois. James,Winschel, Senior ... formal presentation on PAREXEL at 10:05 a.m. EDT on ... presentation will be available through the,"Investor Relations Webcasts" section ...
Cached Medicine News:Health News:Metoprolol around the time of surgery increases the risk of death and stroke: POISE trial 2Health News:Metoprolol around the time of surgery increases the risk of death and stroke: POISE trial 3Health News:Michael A. Sandler, MD, Installed as President of Michigan State Medical Society 2Health News:China Yingxia International, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:First Major Chinese Medical Delegation Visits Minnesota 2Health News:Fairbank Farms Issues Voluntary Recall for Selected Ground Beef Products 2Health News:PAREXEL International to Present at Robert W. Baird's 2008 Growth Stock Conference 2
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
... Accu-Temp Cauteries provide a broad ... cauterization in a wide variety ... use cautery is packaged sterile, ... to lock switch in the ...
... broad selection of tip styles for ... ophthalmic procedures. Each single use cautery ... safety cap to lock switch in ... in use, and carries a 3-4 ...
... PC visual acuity system allows you access ... B-VAT II. The system includes 10 different ... testing and animated characters. Random character sequencing ... single letter, single line and multiple line ...
Medicine Products: